14-0508 PAH/BIOMARKERs QA/QC Summary

| Project: | ANIMIDA III | | |
|-----------------------|--|-----------|--|
| Parameters: | PAH and Biomarkers | | |
| Laboratory: | Battelle, Norwell, MA | | |
| Matrix: | Sediment | | |
| Data Set: | DP-14-0778 | | |
| Analytical SOP: | 5-157 | | |
| Method Reference: | Modified EPA Method 8270D | | |
| | Dossint Data | Tomp (°C) | |
| Sample Custody | Receipt Date | Temp (°C) | |
| | 8/14/2014 | 4.0 | |
| Corrective Actions | None. | | |
| Sample Storage | The samples were stored in an access-limited freezer until sample preparation could begin. | | |
| | METHOD SUMMARIES | | |
| Sample Preparation | The sediment samples were extracted following a modified EPA Method 3510C. Samples were prepared for analysis by weighing approximately 30 grams of sample material into a pre-cleaned extraction vessel and dried using sodium sulfate. Each sample was spiked with PAH, Biomarker and SHC surrogates and extracted 3 times using methylene chloride by shaker table. The combined extracts were dried over sodium sulfate and concentrated by Kuderna-Danish (KD) and nitrogen evaporation techniques. Sample clean-up was performed on the extracts using alumina columns. Extracts were further cleaned up and fractionated using silica gel columns. The F1 fraction was collected and split for TPH/SHC and biomarker analyses. The F2 fraction was collected for PAH and alkyated PAH analysis. The extracts were concentrated and spiked with IS for analysis. | | |
| Prep comments | Several notes about specific samples and the silica columns. Please see the sample specific notes in the Prep section of the package. | | |
| Analysis | PAH, alkylated PAH (F2 fraction) and Biomarkers (F1 fraction) were measured by gas chromatography-mass spectrometry (GC/MS) in the selected ion mode (SIM). An initial calibration consisting of target analytes was analyzed prior to analysis to demonstrate the linear range of analysis. Calibration verification was performed every 24 hours in which samples were analyzed. Concentrations of target compounds were calculated versus internal standards. Target PAH were quantified using the average response factors (RF) generated from the initial calibration. The alkyl homologue PAH series were assigned the RF of the parent PAH. Biomarkers used RFs from the single individual biomarkers within the calibration standard curve. All reported data (except NSC and CO) is corrected | | |

based on surrogate recoveries.

14-0508 PAH/BIOMARKERs QA/QC Summary

| | All data is reported on dry weight basis except the NSC and CO (oil weight). | |
|-------------------|--|---------------------|
| Analysis comments | None. | |
| Holding Times | Extraction Date(s) | Analysis Date(s) |
| | 10/27/2014 & 11/3, 5, 18/2014 | 11/9-12, 19-21/2014 |

| Procedural Blank (PB) | A PB was prepared with this analytical batch to ensure the sample extraction and analysis methods are free of contamination. |
|---|--|
| PB <5 X MDL | One exceedence noted. |
| Samples must be >5x PB | Comments: There is one MQO exceedence for the presence of |
| | Naphthalene in a qualified authentic sample at a concentration less |
| | than five times the amount found in the procedural blank. |
| | · |
| Laboratory Control Spike (LCS) | A LCS was prepared with this analytical batch. The percent |
| | recoveries of target analytes were calculated to measure accuracy. |
| Recovery of 70-130% | No exceedences noted. |
| , | Comments: None. |
| | |
| Surrogate Recovery | Surrogate compounds were added prior to extraction. The surrogate |
| Surrogate Necovery | recoveries are calculated to measure extraction efficiency. |
| Recovery of 40-120% | No exceedences noted. |
| Recovery 01 40-120% | |
| | Comments: None. |
| Matrix Chiles and Matrix Chiles | A NAC /NACD was proposed with this small tired batch. The proposet |
| Matrix Spike and Matrix Spike | A MS/MSD was prepared with this analytical batch. The percent |
| Duplicate (MS/MSD) | recoveries of target analytes were calculated to measure accuracy. |
| | The RPD of target analytes were calculated to measure data quality |
| December of 70 1200/ | in terms of accuracy. |
| Recovery of 70-130% | No exceedences noted. |
| Relative Percent Difference (RPD) < 30% | Comments: None. |
| (=) | |
| Standard Reference Material | An SRM was prepared with this batch to assess accuracy of the |
| (SRM) | analytical procedures. |
| < 30 PD from target | No exceedences noted. |
| concentration and the 95% | Comments: None. |
| confidence level analyte | |
| concentration must be $> 5x$ the | |
| MDL. Concentration must be | |
| certified and >5x the MDL for | |
| MQO to apply | |
| / | |
| North Slope Crude (NSC) | A NSC Reference Oil was prepared with this batch to evaluate the |
| 1 (7 | instrumental accuracy and also provide petroleum pattern |
| | information, aiding in the qualitative identification of target analytes. |
| | |

14-0508 PAH/BIOMARKERs QA/QC Summary

| | The control oil also run in this batch has no associated target values |
|--------------------------------|--|
| | and is not evaluated. |
| < 30% RPD for 90% of analytes; | No exceedences noted. |
| Concentration must be >5x the | Comments: None. |
| MDL for MQO to apply. | |
| 11, | |
| Initial Calibration (ICAL) | The GC/MS is calibrated with a minimum 5 level curve for all |
| Initial Campitation (IC/LZ) | compounds. |
| | compounds. |
| | |
| | |
| Individual RSD ≤25%; Mean | No exceedences noted. |
| RSD ≤15% | Comments: None. |
| | |
| | |
| Independent Calibration Check | The independent check was run after each initial calibration to verify |
| (ICC) | the calibration. This standard is from a different source than the |
| (100) | ICAL. |
| | TO IL. |
| Individual and Mean PD ≤25% | No exceedences noted. |
| | Comments: None. |
| | |
| | |
| Continuing Calibration | Continuing calibration standards were run every 24 hours to ensure |
| Verification (CCV) | that initial calibration is still valid. |
| , , | |
| Individual RSD ≤25%; Mean | No superdenses weterd |
| RSD ≤15% | No exceedences noted. |
| K2D 712‰ | Comments: None. |
| | |